Press Releases

 
Press Releases
Date Title and Summary View
Sep 1, 2015 PORTLAND, Ore., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer, w...
Aug 24, 2015 PORTLAND, Ore., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that the Independent Data Monitoring Committee (IDMC) has recommended ...
Aug 6, 2015 Completed over-enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial and presented encouraging data for GALE-301 and GALE-401 programsAchieved net revenue of $3.4 million for Q2, totaling $6.1 million for 1H, 2015 from Abstral® (fentanyl) Sublingual Tablets; Launched Zuplenz® (ondansetron) Oral Soluble Film i...
Jul 29, 2015 Zuplenz is indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV)Novel, oral soluble film technology provides convenient delivery and key patient benefits PORTLAND, Ore., July 29, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, In...
Jul 28, 2015 PORTLAND, Ore., July 28, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that the Company will report its second quarter 2015 financial results on Th...
Jun 15, 2015 GALE-401 was well tolerated with primarily Grade 1 and 2 toxicitiesPhase 2 pilot study demonstrated an Overall Response Rate of 78% PORTLAND, Ore., June 15, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medic...
May 28, 2015 PORTLAND, Ore., May 28, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer wil...
May 27, 2015 GALE-301 demonstrates promising preliminary efficacy data with a projected 78% reduction in relative risk of recurrence in the 1000 mcg dose cohort Leica Biosystem's Bond Oracle HER2 Immunohistochemistry (IHC) System distinguishes HER2 1+ and 2+ expressions and supports its use as a companion diagnostic for NeuVax™ (nelipepimut-S) PO...
May 22, 2015 PORTLAND, Ore., May 22, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's Phase 2 clinical trial of GALE-401, or Ana...
May 7, 2015 Completed enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial Commercial programs continue on trackAbstral® (fentanyl) Sublingual Tablets achieve net revenue of $2.8 million; full year 2015 net revenue guidance reiterated at $15-$18 millionZuplenz® (ondansetron) Oral Soluble Film product launch targeted for...
Page:
1
... NextLast
= add release to Briefcase